Literature summary for 3.4.21.61 extracted from

Careskey, H.E.; Davis, R.A.; Alborn, W.E.; Troutt, J.S.; Cao, G.; Konrad, R.J.
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 (2008), J. Lipid Res., 49, 394-398.

Search for more literature for 3.4.21.61

Activating Compound

Activating Compound	Comment	Organism	Structure
atorvastatin	significantly increases circulating PCSK9 levels by 34% compared with baseline and placebo and decreases low density lipoprotein cholesterol levels by 42%	Homo sapiens

Application

Application	Comment	Organism
medicine	PCSK9 is an attractive drug target for decreasing low density lipoprotein cholesterol levels. Addition of a PCSK9 inhibitor to statin therapy may result in even further low density lipoprotein cholesterol level decreases	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
serum	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
PCSK9	-	Homo sapiens
proprotein convertase subtilisin/kexin type 9	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)